PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of

PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta Psycan announces that Blue Cross Alberta has issued a notice to prescribers that it will reimburse patients for Psychedelic-Assisted Therapy

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy PsyCan Endorses Senate Report into Psychedelic Treatments for Veterans

The Future of Psychedelic Access in Canada: PsyCan Releases White Paper Reviewing Regulatory Options for Psychedelics PsyCan, the trade association for the for-profit psychedelic medicine industry, releases a white paper on how Health Canada can improve access to therapies